TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (566)	1/12/2006 2:03:06 PM
From: Biomaven	Read Replies (1) of 887

Nope, that link doesn't work. But I have access, and I really like this quote: One patient who presented with platinum and paclitaxel refractory disease achieved a durable CR. This patient had stage IV ovarian cancer and was treated by inadequate debulking surgery followed by carboplatin and paclitaxel. She progressed during her sixth cycle, exhibiting measurable bulky (5 cm) disease in liver and spleen (target lesions), ascites, and diffuse abdominal metastases that were nonmeasurable, and a rising CA125 level of 36. After two cycles (6 weeks) of TLK286, the patient had a robust PR, and after completing six cycles of TLK286, the patient experienced a confirmed CR. The patient continues in complete remission for more than 3 years and off all therapy for more than 2.5 years Only one patient, but that's an incredible result on monotherapy. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next